Islet Sciences licenses noninvasive technology for detecting Beta cell death from Winthrop

Islet Sciences licenses noninvasive technology for detecting Beta cell death from Winthrop

Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

“In the course of research conducted under Winthrop University Hospital, Dr. Eitan Akirav and his colleagues at Winthrop have developed a technology entitled Method for Using Probe Based PCR Detection to Measure the Levels of Circulating Demethylated Beta Cell Derived DNA as a Measure of Beta Cell Loss in Diabetes,” stated John Steel, Chairman and CEO of Islet Sciences. “We are pleased to bring this groundbreaking technology to the next level as we look to commercialize it to benefit the growing worldwide diabetic community. There has been a long-felt need for a method capable of accurately evaluating Beta cell death so as to improve disease diagnosis, allow for disease staging, and provide a better evaluation of clinical treatment efficacy. The method can identify Beta cell death before the onset of hyperglycemia and soon after the onset of T1D.”

“The method provides a noninvasive approach for detecting Beta cell death in vivo that may be used to track the progression of diabetes and guide its treatment,” said Dr. Eitan Akirav, Research Scientist at Winthrop University Hospital. “I am excited to work with Islet Sciences to bring this technology to market which clearly has so much potential. The method uses a stepwise detection and analysis of Beta cell and non-Beta cell derived insulin DNA. The key principle behind the method is the existence of unique DNA methylation patterns in the Beta cells that are absent from other cells in the body.”

Alan M. Jacobson, MD, Chief Research Officer, Director of the Diabetes, Obesity and Cardiometabolic Research Center and Senior Scientist, Winthrop University Hospital Research Institute commented, “We look forward to working with Islet Sciences as they invest in this discovery and develop it into a valuable new tool for treating this life altering disease.”

Source : http://www.news-medical.net/news/20120910/Islet-Sciences-licenses-noninvasive-technology-for-detecting-Beta-cell-death-from-Winthrop.aspx

Related Posts Plugin for WordPress, Blogger...
Be Sociable, Share!

About the Author

has written 1822 posts on this blog.

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes